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Abstract: Chronic obstructive pulmonary disease (COPD) is a major public health problem, 
associated with considerable morbidity and health care costs. The global burden of COPD 
morbidity is predicted to rise substantially in the coming decade, but could be moderated by 
better use of existing management strategies. Smoking cessation, medication therapy, and pul-
monary rehabilitation have all been shown to diminish morbidity and improve patient outcomes. 
But each of these strategies requires adherence. Adherence is crucial for optimizing clinical 
outcomes in COPD, with nonadherence resulting in a significant health and economic burden. 
Suboptimal medication adherence is common among COPD patients, due to a number of fac-
tors that involve the medication, the delivery device, the patient, and the health professionals 
caring for the patient. Lack of medication adherence needs to be identified and addressed by 
using simplified treatment regimens, increasing patient knowledge about self-management, 
and enhancing provider skills in patient education, communication, and adherence counseling. 
This article reports some of the challenges of medication nonadherence faced by the clinician 
in the management of COPD, and suggests ways to evaluate and improve adherence effectively 
in primary care.
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Introduction
Nonadherence in patients with chronic diseases is estimated to cost $300 billion in the 
US annually, with COPD among the conditions with the lowest levels of adherence.1 
Acute and maintenance treatment of COPD relies on inhaled agents to manage and 
control symptoms and/or complications of the disease, and prevent exacerbations.2 
Therefore, adherence to inhaled agents is required to manage and control symptoms 
and to prevent or delay complications of COPD, including exacerbations.2,11 The rate 
of .50% poor adherence in the COPD population3–8 is not surprising, because people 
with COPD usually have multiple morbidities and take an average of six medications.9 
In 2005, the global mortality rate for COPD was over three million. This figure is set 
to rise by over 30% in the coming decade, unless adequate preventive strategies are 
implemented.10
While everyone agrees that nonadherence is a major problem, there is no universal 
agreement on how to define adherence. Older definitions of adherence often used the 
term compliance, suggesting a more paternalistic relationship where patients play a 
passive role in their care, ie, the patient is “compliant” if they follow “orders”. An 
alternative definition that is gaining wide acceptance is that adherence is the degree of 
concordance (or agreement) between the health professional’s recommended therapy International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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and the patient’s actual behavior. Concordance indicates a 
partnership between the patient and health care provider, and 
adherence implies that patients and clinicians work together in 
this partnership. Adherence therefore implies that the patient 
has an active role in consenting to, and following, prescribed 
treatments. Using the concept of concordance provides many 
additional avenues to work towards improved adherence.
This article reports on the proceedings of an advisory board 
discussing the “Implications of inhalation delivery systems for 
COPD therapies” (held in New York City, NY, March 25–26, 
2009), and discusses the challenges surrounding nonadherence 
in COPD patients, assesses nonadherence and the determinants 
for nonadherence, and addresses how adherence could be 
improved by better clinician-patient communication.
Challenge of nonadherence  
in COPD
There are a number of reasons for suboptimal adherence to 
medications in patients with COPD, as well as other chronic 
diseases.11 Adherence tends to decline over time with chronic 
medication use, and is inversely related to the number of 
medications taken by the patient.11,12 These factors alone make 
adherence an even larger problem with COPD patients who 
require lifelong therapy after symptomatic COPD is diagnosed. 
In the Lung Health Study, a subset of 5887 COPD patients were 
studied for compliance with inhaler use by both self-report and 
canister weight. Inhaler compliance demonstrated a consistent 
decline over five years from .60% at year 1 to ,50% compli-
ance by year 5.13 These findings are consistent with another 
five-year study of medication use in obstructive lung disease 
patients, where 51% acquired their prescribed drugs less than 
once per year.4 In a Swedish study of patients aged $60 years 
with COPD or asthma, only 28% of patients had “satisfac-
tory” refill patterns (ie, dispensed refills covering .80% of 
the prescribed treatment time) of their inhaled corticosteroid 
(ICS).14 In a study of 11,376 COPD patients in the last year 
of life, only 52% used any COPD medications.14
Data on adherence issues among patients with asthma 
are useful in projecting potential issues for COPD patients. 
Like COPD, asthma is a chronic condition that relies heavily 
on inhaled medications and less on the ingestion of tablets. 
Patients with COPD, as well as those with asthma, may be 
on as many as 3–4 different types of inhalers that require 
mastery. The challenges of inhaler mastery for the COPD 
patient are more numerous than for asthma, because COPD 
patients are usually older with multiple comorbidities, as well 
as impaired physical and cognitive function that may interfere 
with inhaler adherence and proper use. Some studies suggest 
that adherence may be worse for those using medications 
for COPD than for other chronic diseases such as diabetes, 
where adherence was 68% versus only 42% for asthma/
COPD medications.6
COPD is a chronic disease and in many patients, includes 
the need to treat one or more exacerbations each year. Drug 
therapy with long-acting bronchodilators, ICS, or a   combination 
of both, has been shown to reduce exacerbations in patients 
with moderate to severe COPD.15 However, patients often 
report they do not see an obvious link between taking their 
medication and an immediate effect on their symptoms.
Furthermore, prior to progressing to severe disease, many 
patients do not consider their condition sufficiently serious 
to require long-term therapy.6,16 Adding to this disconnect 
between their COPD and its treatment, many patients discon-
tinue their medication in response to a decline in symptoms17 
or the complexity of the treatment regimen.5 Patients report 
they worry that they will develop tolerance to the inhaled 
medications if they take them regularly over the long term, 
believing that the medication will be less effective when they 
really need it, such as during an exacerbation.18
Determinants of adherence
Adherence in patients with COPD is affected by multiple fac-
tors associated with the patient, their clinician, and society11 
(see Figure 119). Patient-related factors include health beliefs, 
cognitive ability, self-efficacy, comorbidities, psychologic 
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Figure 1 Patient adherence in chronic obstructive pulmonary disease is multifactorial 
and is influenced by the patient, the clinician, and society.
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profile, and conscientiousness. For example, depression is a 
major cause of nonadherence in COPD patients, but is seldom 
recognized or acknowledged.16,20,21 Treatment-related factors 
include the need to use multiple inhalers, each requiring a 
different technique for administration, posing challenges for 
the older COPD patient. Societal factors include the patient-
prescriber relationship, social support, access to medication, 
device training, and follow-up. Training the COPD patient on 
the various inhaler devices is fraught with the potential for 
incorrect delivery and administration of the medication, even 
among patients who want to take their inhaler correctly.
There are a number of other factors that, perhaps 
unexpectedly, are not reliably associated with adherence, 
including age, gender, race, income, education, personal-
ity, and adherence to other medications.6,16 It is important 
to understand that human behavior is a key consideration 
when evaluating what influences adherence.22 For example, 
it seems reasonable to assume that patients who seek help 
from their clinician will want to take the medication they are 
prescribed, and that it would be illogical not to comply with 
the advice and instructions they receive. Nonadherence may 
appear to be an irrational act from the clinician’s perspective, 
but completely rational from the patient’s perspective.
Assessing adherence
Assessing adherence is a complex issue, with many aspects 
of adherence remaining poorly defined and understood. At 
present, there is no general agreement about how to define 
“optimal” or “adequate” adherence, or which of these should 
be measured in trials and clinical practice. Questions remain 
about what is an “acceptable” level of adherence to achieve 
disease control. For example, if the patient’s symptoms are 
under control and they are satisfied with symptom control, 
is that level of adherence acceptable? Different medications, 
regimens, and behaviors all have a varying impact on adher-
ence. The main methods for assessing adherence are clini-
cian estimates, patient self-reporting, pill counts/weighing, 
pharmacy records, biologic markers, and electronic monitor-
ing. The advantages and disadvantages of these adherence 
measures are summarized in Table 1.
Clinician estimates, such as patient self-reports, have been 
shown to be unreliable.19,23 Studies in asthma patients have 
shown that patient self-reporting and pill counts can yield 
very misleading results, primarily because patients want their 
clinicians to be happy with them. Patients will tend to exag-
gerate their medication use in self-reports.24–26 Pill (or dose) 
counting on the other hand can lead to overestimates. In the 
latter case, patients have been found to empty pills from their 
packaging or empty their inhalers deliberately when they 
realize a primary care visit is imminent.27 Pharmacy data sets 
have been used, but only confirm that a prescription has been 
filled, not if the drug has been inhaled or ingested. Biologic 
measures would appear to be precise; however, they are not 
currently able to detect the presence of inhaled drugs and 
are only available for a limited number of oral medications. 
Electronic monitoring can provide more accurate data on pat-
terns of medication use24 but these monitors are expensive, of 
limited availability, do not necessarily indicate the patient has 
taken the dose, and are susceptible to malfunction. Improved 
electronic monitoring devices are needed to evaluate each of 
available types/designs of inhaled devices.
Patient-clinician communication
Effective communication between the clinician and patient 
is crucial for optimizing adherence.11,22 Patients with poor 
adherence have been shown to have a low level of satisfaction 
and faith in their clinician.22 In a study of ICS use in asthma 
patients, the most powerful predictor of nonadherence was 
the belief that they did not need to take as much ICS as the 
doctor prescribed.18 Assessing and discussing the patients’ 
illness perceptions and attempting to bring perception in 
closer alignment with evidence has been shown to improve 
patients’ quality of life and clinical outcomes.28
Proper education ensures the patient is fully informed 
about the important aspects of their treatment regimen, from 
the practicalities of administration to the rationale for taking 
the medication.29–32 In practice, most patients receive inad-
equate education about proper use of their drug therapy.33 An 
observational study of 44 physicians demonstrated that full 
medication directions (specific medication name, purpose of 
medication, dosing quantity and frequency, adverse effects, 
Table  1 Advantages  and  disadvantages  of  different  adherence 
measures
Advantages Disadvantages
Clinician estimates easy to obtain Unreliable 
Patient self-reports easy to obtain Unreliable 
Pill counts/weighing easy to obtain Overestimates use
Pharmacy records Confirms 
prescription filling
Incomplete, biased  
estimates
Biologic measures Confirms ingestion expensive, invasive, 
insensitive to inhaled 
drugs, affected by 
pharmacokinetics and 
polypharmacy
electronic 
monitoring
Patterns of use, 
ingestion
expensive, limited  
availability and use,  
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and patient’s perspective), long-term safety concerns, 
news about relevant clinical studies in the media, and 
new therapies.
Clinicians need to be vigilant for “red flags” indicating 
poor adherence (Table 2). Areas that are associated with poor 
adherence include denial, disruption (eg, personal crises), 
depression, and dementia. The clinician should not anticipate 
good adherence when any of these four factors are present.
Addressing adherence problems
Nonadherence can be either unintentional or intentional.11,30 
Three forms of nonadherence have been identified, ie, erratic, 
unwitting, and intelligent.26 Erratic nonadherence occurs 
when the patient understands and agrees with therapy but 
has difficulty consistently maintaining the regimen. This 
difficulty may be attributable to a busy schedule, to lack 
of attention to detail, or to inadvertently forgetting to take 
their medication. Patients prone to this type of nonadher-
ence may be forgetful, disorganized, or may simply run out 
of medication. Patients with complex medication regimens 
or a frequent change of schedule may also have episodes of 
erratic nonadherence. Using a once-daily medication may 
increase adherence in this group.37
Unwitting nonadherence describes when both the patient 
and provider mistakenly believe that the patient is   adherent. 
For example, unwitting nonadherence may occur in the 
patient who misunderstands their medication regimen or 
forgets instructions, perhaps due to language barriers or 
cultural differences. Unwitting nonadherence is a particular 
danger in COPD patients due to the complexity of inhaler 
use. Were they properly trained? Were they observed in 
their use of each of their inhalers? Were they observed 
on subsequent visits? Patient retention of the various steps 
in inhaler use can easily confuse the patients. Patients with 
cognitive impairment, depression, or anxiety disorders have 
difficulty recalling instructions and should be provided with 
written instructions.
Intelligent nonadherence occurs when the patient delib-
erately alters or discontinues therapy based on reasoned 
decision-making about their perceptions of the drug’s 
efficacy, likelihood of long-term harm, and their social 
Table 2 Red flags for poor adherence
Red flag Details
Denial Patient beliefs about illness and therapy
Disruption Personal and family crises
Depression Apathy and withdrawal
Dementia Psychiatric or related to substance abuse
and duration of treatment regimen) were conveyed to less 
than 60% of 185 patients.33
Many primary care clinicians are not fully aware of 
COPD management guidelines, eg, the Global Initiative for 
Chronic Obstructive Lung Disease2 and, therefore, may not 
be sufficiently equipped to educate patients about all aspects 
of managing their disease.34,35 Unfortunately, education is 
given a low priority, and budgetary constraints often lead 
to insufficient numbers of educators devoted to the needs of 
the pulmonary patient.
Tailoring treatment to fit the individual’s needs, abili-
ties, and preferences is a key element of COPD manage-
ment. This can be best accomplished by having patients as 
active participants in treatment decisions. COPD patients 
with self-management plans tend to have better awareness 
and adherence.20 Communication at the time of a new 
prescription plays an important role in future adherence, 
including whether the first prescription is filled. Therefore, 
when initiating new therapies, the clinician may increase 
their success in adherence of their patient by: explaining 
the roles of the different types of therapy in disease man-
agement, then asking the patient about their understanding 
of each prescribed therapy, and any gaps in the patient’s 
knowledge or misunderstandings can then be addressed, 
describing the medical criteria for assessing disease con-
trol and asking the patient about their expectations and 
what criteria they use for decision-making (eg, long-term 
safety concerns); assessing each patient’s preferences and 
possible barriers to adherence, including fears, beliefs, 
financial, social, cultural, and practical issues, such as 
transportation;36 providing written medication plans for the 
patient to take home, especially for those with cognitive 
issues or anxiety, who may not be able to retain information 
given verbally; encouraging telephone calls/email contact 
between visits with the clinician, a medical assistant, or 
nurse, to clarify questions about their medications (clini-
cians’ concern that they will be inundated with patient 
queries has not been borne out in practice); and discussing 
adherence in a nonthreatening way is pivotal to gaining the 
patient’s trust to discuss their difficulties with adherence. 
Acknowledge to the patient that adherence to a regime, 
especially a regimen requiring multiple medications, is 
difficult. Effective communication needs to be maintained 
throughout ongoing management so that adherence can be 
explored in a nonthreatening and nonjudgmental manner. 
The physician/clinician should discuss issues related to 
adherence, such as satisfaction with treatment, criteria 
for disease control and efficacy (from both the medical International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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  circumstances.38 Signs of this type of nonadherence include 
comments about feeling better and no longer needing the 
medication, concern about toxicity, perceived ineffectiveness 
of therapy, fear of tolerance, and a general opinion that taking 
as little medicine as possible is best. Once the type of non-
adherence has been identified, adherence interventions can 
be matched to the source of nonadherence. Table 3 describes 
interventions for these three types of nonadherence.
Conclusion
Adherence to medication in COPD is crucial for opti-
mizing clinical outcomes, and nonadherence results in a 
significant health and economic burden. Suboptimal adher-
ence is common among COPD patients and results from 
a complex interplay of medication, patient, and provider 
factors. Adherence could be improved by using simplified 
treatment regimens, increasing patient knowledge about 
self-management, and enhancing provider skills in patient 
education, communication, and adherence counseling. The 
challenge of adherence is determining acceptable levels 
of adherence and simple, but reliable devices to measure 
adherence. Given the numerous inhalers available to treat 
COPD, electronic monitors to evaluate all of these medica-
tions have not as yet been developed. Clinical trials using 
electronic monitoring, therefore, need to be conducted to 
investigate the feasibility of adherence interventions, their 
effects on clinical outcomes, and the durability of results.
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